The role of miRNA- 96 and miRNA-150 between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients

Abstract

BackgroundDysregulation of miRNA expression patterns is one of the several effects developments of cancer. MiRNA has been found to express abnormally in hematological neoplasia such as chronic myeloid leukemia and solid malignancies. Resistance and the degree of response following tyrosine kinase inhibitor (TKI (treatment are correlated with miRNA expression. Hence this study has evaluated the correlation between miRNA- 96 and miRNA-150 with different p210 BCR-ABL transcript levels and the role of miRNA- 96 and miRNA-150 at different levels of imatinib optimal response in CML patients. MethodThis study is based on 60 CML patients divided into two groups based on response to imatinib therapy. 30 samples have the optimal molecular response of CML patients. The other 30 samples that have failed molecular response CML patients, which were compared to 30 samples of healthy volunteers as control by depending on the results of CBC film and PCR. BCR-ABL 210 transcript, which was used in this study, is obtained from the patient's file. ResultsThe results based on the comparison of transcript levels showed that there was a significant difference between the positive response and failed response of CML patients (P ≤ 0.0001). The result of miRNA-96 showed that there was no noteworthy difference within both CML patients (P ≥ 0.5030), while miRNA-150 results exhibited a high significant difference (P ≤ 0.0001). The miRNA-96 and miRNA-150 expression levels in all responses of CML patients demonstrated a highly significant difference with P = 0.0134 and P = 0.0002, respectively. The cut-off value of response against failure response of miRNA-96 and miRNA-150 with P value of 1.691 and 1.784, respectively with high sensitivity is a diagnostic value of the difference between the response and failure response. Conclusionmodulating gene expression with different of miRNAs expression has an impact on drug-gene interactions, with consequences for cell growth and death. The gene expression that shows the different level miRNAs (miRNA- 96 and miRNA-150) among of CML patients of imatinib therapy exhibited high expression in response patients than that of the failure response of patients. The gene expression level of miRNA- 96 and miRNA-150 was differed between through different response CML patients.